The PTPRZ1::MET fusion has been reported in the literature in only a few isolated cases, is most often identified in brain metastases from NSCLC rather than in primary tumors, and is predominant in patients previously treated with TKIs. This evidence concerns the gene PTPRZ1 and non-small cell lung carcinoma.